Active	Status	Sponsor type	Region	Phase	Filter
4 Active 2 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
tempol (MBM-02) / DMK Pharma, Matrix Biomed
NCT04876755: MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer	Not yet recruiting	2	55	US	MBM-02, Tempol; 4-hydroxy-tempo; 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl	Matrix Biomed, Inc., Prostate Oncology Specialists	Prostate Cancer Recurrent, Biochemical Recurrent Prostate Cancer	09/22	02/23
NCT04874506: MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM)	Not yet recruiting	2	55	US	MBM-02, Tempol; 4-hydroxy-tempo; 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl	Matrix Biomed, Inc., MedStar Georgetown	Glioblastoma, Glioblastoma Multiforme	01/23	08/23
NCT04337099: A Single Patient Compassionate Use of MBM-02 (Tempol) for the Treatment of Prostate Cancer	Available	N/A		US	MBM-02 (Tempol), Tempol; 4-hydroxy-tempo; 4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl	Matrix Biomed, Inc.	Prostate Cancer
NCT05491928: Treatment of Metastatic Cancer in Terminally Diagnosed Patients	Available	N/A		US	Tempol, MBM-0-1 MBM-02	Matrix Biomed, Inc.	Metastatic Cancer
tempol (APC-400) / DMK Pharma
No trials found